[Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease]

Gac Med Mex. 2017;153(Supl. 2):S72-S81. doi: 10.24875/GMM.M000008.
[Article in Spanish]

Abstract

Objective: To determine the effect of melatonin (MEL) administration on ciclooxigenase 2 (COX-2) activity and serum concentration of nitric oxide metabolites, lipoperoxides and glutathione peroxidase (GPx) activity in patients with Parkinson's disease.

Methods: Prospective double-blind randomized clinical pilot trial. 13 patients were included and two groups were formed: MEL at doses of 25 mg orally every 12 hours for 12 months and placebo with corn starch. Patients were assessed using the Unified Parkinson's Disease Scale. A blood sample was taken at baseline and every 3 months until 12 months.

Results: COX-2 activity decreased as did nitrates/nitrites (3, 6 and 9 months) and lipoperoxides (9 and 12 months); GPx exhibited no significant differences.

Keywords: 4-OH-alkenes; Ciclooxigenase 2; Glutathione peroxidase; Malon-dialdehyde; Nitrates/nitrites; Parkinson.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antioxidants / administration & dosage
  • Antioxidants / pharmacology*
  • Cyclooxygenase 2 / metabolism*
  • Double-Blind Method
  • Glutathione Peroxidase / blood*
  • Humans
  • Lipid Peroxides / blood*
  • Melatonin / administration & dosage
  • Melatonin / pharmacology*
  • Nitric Oxide / metabolism*
  • Oxidative Stress
  • Parkinson Disease / metabolism*
  • Pilot Projects
  • Prospective Studies

Substances

  • Antioxidants
  • Lipid Peroxides
  • Nitric Oxide
  • Glutathione Peroxidase
  • Cyclooxygenase 2
  • Melatonin